Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of 4-Guanidino-Benzoic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.55 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.55 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MITF | O75030 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 4-Guanidino-Benzoic Acid SCHEMBL10674543 | 1.00 | F2 (0.55) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL28796971 | 0.98 | F2 (0.53) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL211005 | 0.98 | F2 (0.57) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL22127093 | 0.96 | F2 (0.55) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL11123754 | 0.96 | F2 (0.55) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL22127091 | 0.94 | F2 (0.58) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL7563601 | 0.89 | CA2 (0.50) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL19205978 | 0.89 | CA2 (0.50) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| 4-Guanidino-Benzoic Acid SCHEMBL9303333 | 0.88 | F2 (0.61) | F2PRSS1PRSS2PRSS3TMPRSS6 | |
| Hydrochloric Acid SCHEMBL11226180 | 0.86 | F2 (0.57) | F2PRSS1PRSS2PRSS3TMPRSS6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119212415-A | Perovskite solar cell and preparation method thereof | 国网甘肃省电力公司电力科学研究院 | 2024-12-27 | — | — | CN | claimed |
| CN-115915788-A | Perovskite solar cell and preparation method thereof | 无锡极电光能科技有限公司 | 2023-04-04 | — | — | CN | claimed |
| CN-114805141-A | 4-guanidinobenzoic acid aryl ester compound and application thereof in resisting SARS-CoV-2 virus | 中国科学院上海药物研究所 | 2022-07-29 | — | — | CN | claimed |
| CN-114315651-A | Preparation method of p-guanidinobenzoic acid hydrochloride | 安徽昊帆生物有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-112827368-A | Anti-pollution reverse osmosis membrane and preparation method thereof | 中化(宁波)润沃膜科技有限公司 | 2021-05-25 | — | — | CN | claimed |
| CN-109792996-B | Avermectin nano-powder and preparation and use method thereof | 中国农业科学院农业环境与可持续发展研究所 | 2021-04-09 | — | — | CN | claimed |
| CN-111574409-A | Recrystallization process method of nafamostat mesylate | 河北省医疗器械与药品包装材料检验研究院(河北省医疗器械技术审评中心) | 2020-08-25 | — | — | CN | claimed |
| CN-109792996-A | A kind of Avermectins nano powder and its preparation and application method | 中国农业科学院农业环境与可持续发展研究所 | 2019-05-24 | — | — | CN | claimed |
| US-20160296449-A1 | Semi-Permanent Hair Straightening Composition And Method | LUBRIZOL ADVANCED MATERIALS, INC. | 2016-10-13 | — | — | US | claimed |
| EP-3065831-A1 | SEMI-PERMANENT HAIR STRAIGHTENING COMPOSITION AND METHOD | Lubrizol Advanced Materials, Inc. (US) | 2016-09-14 | — | — | EP | claimed |
| CN-103641749-B | A kind of preparation method of nafamostat mesylate | SHANDONG YONGTAI CHEMICAL Co.,Ltd. (CN) | 2016-02-10 | — | — | CN | claimed |
| WO-2015069823-A1 | SEMI-PERMANENT HAIR STRAIGHTENING COMPOSITION AND METHOD | LUBRIZOL ADVANCED MATERIALS, INC. (US) | 2015-05-14 | — | — | WO | claimed |
| CN-103641749-A | Preparation method of nafamostat mesylate | SHANDONG YONGTAI CHEMICAL CO | 2014-03-19 | — | — | CN | claimed |
| US-12610734-B2 | Organic-inorganic hybrid perovskites | CITY UNIVERSITY OF HONG KONG (CN) | 2026-04-21 | — | — | US | disclosed |
| US-12408548-B2 | Perovskite layer, fabrication method and use the same | CITY UNIVERSITY OF HONG KONG (HK) | 2025-09-02 | — | — | US | disclosed |
| US-20250188022-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2025-06-12 | — | — | US | disclosed |
| EP-0048433-A2 | Novel amidine compounds, process for producing same and anti-complement agent comprising them | TORII & CO., LTD. (JP) | 1982-03-31 | — | — | EP | disclosed |
| US-4179511-A | Antibacterial 3-(5-tetrazolyl) penam compounds | PFIZER INC. (US) | 1979-12-18 | — | — | US | disclosed |
| US-4143039-A | ANTIBACTERIAL 3-(5-TETRAZOLYL)PENAM COMPOUNDS | PFIZER INC. (US) | 1979-03-06 | — | — | US | disclosed |
| US-4115385-A | PENICILLINS | PFIZER INC. (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250188022-A1 | PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES | TPMT, ADH1C, ADH1A | CA2 588/4885F2 1213/4885PRSS1 1209/4885 |
| US-12408548-B2 | Perovskite layer, fabrication method and use the same | KCNQ1, KCNQ2, SCNN1B | CA2 895/4885F2 4794/4885PRSS1 2304/4885 |
| US-20160296449-A1 | Semi-Permanent Hair Straightening Composition And Method | KRT18, PRKDC, DNMT1 | CA2 3006/4885F2 1386/4885PRSS1 3492/4885 |
| US-12610734-B2 | Organic-inorganic hybrid perovskites | CHN2, AR, H1-2 | CA2 55/4885F2 4229/4885PRSS1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.